Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Nervous System Diseases
Conditions
Interventions
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record by the end date of the deferral (24 Jan 2
Sponsors
Alfred E. Tiefenbacher (Germany)
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record by the end date of the deferral (24 Jan 2026)
Exclusion criteria
Exclusion criteria: The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record by the end date of the deferral (24 Jan 2026)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record by the end date of the deferral (24 Jan 2026) | — |
Secondary
| Measure | Time frame |
|---|---|
| The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record by the end date of the deferral (24 Jan 2026) | — |
Countries
England, United Kingdom
Contacts
Public ContactTrial Lead
Outcome results
None listed